The study that is redefining FRα-positivity in platinum-resistant ovarian cancer¹´²

Previous studies of FRα-targeted therapy have failed to capture a majority of patients with FRα-expression²′³

of platinum-resistant ovarian cancer patients are potentially eligible for REFRαME-O1

The REFRαME-O1 study aims to expand the definition of actionable FRα-expression, extending the opportunity for targeted therapy to more patients.

Folate receptor alpha (FRα) is a validated target that is overexpressed in ovarian cancer compared with normal tissue3,4. The REFRαME-O1 study in platinum-resistant ovarian cancer is part of the REFRαME trial program, which seeks to reframe our understanding of actionable FRα expression across a range of tumor types.

A registrational directed study of luveltamab tazevibulin in platinum-resistant ovarian cancer, a next generation ADC developed using XpressCF+® cell-free technology¹

Trial design to support accelerated approval

Email Sutro at to learn more

References: 1. Data on file. Sutro Biopharma, Inc. 2. Matulonis UA, Lorusso D, Oaknin A, et al. Efficacy and safety of mirvetuximab soravtansine in patients with platinum-resistant ovarian cancer with high folate receptor alpha expression: results from the SORAYA study. J Clin Oncol. 2023;41(13):2436-2445. 3. Birrer MJ, Betella I, Martin LP, Moore KN. Istargeting the folate receptor in ovarian cancer coming of age? Oncologist. 2019;24(4):425-429. 4. Bax HJ, Chauhan J, Stavraka C, et al. Folate receptor alpha in ovarian cancer tissue and patient serum is associated with disease burden and treatment outcomes. Br J Cancer. 2023;128(2):342-353.

Copyright © 2024 Sutro Biopharma, Inc. South San Francisco, California, USA